Form 4: Agenus CEO Takes Salary in Stock

Agenus Inc.'s Chairman and CEO, Garo H. Armen, acquired 4,942 shares of common stock as part of his salary for the pay period ending December 26, 2025.

Summary

• Garo H. Armen, Chairman and CEO of Agenus Inc., acquired 4,942 shares of common stock.
• The transaction occurred on December 26, 2025, at a price of $3.31 per share.
• This acquisition represents the net amount of Dr. Armen's salary for the pay period ending December 26, 2025, paid in stock instead of cash.
• The shares were issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
• Following this transaction, Dr. Armen directly beneficially owns 307,343 shares of common stock.
• He also indirectly beneficially owns 31,298 shares in IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.

Sentiment

Score: 7

Explanation: The CEO's decision to take salary in stock is a positive signal of confidence in the company's future, aligning management interests with shareholders. This is a routine, pre-arranged transaction, so it's not a major event but still a good sign.

Positives

• The CEO's decision to take salary in stock demonstrates confidence in the company's future performance and aligns his interests with those of shareholders.
• The shares are fully vested upon issuance, indicating immediate ownership and commitment.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Future Outlook

The filing does not contain any specific forward-looking statements or guidance.

Management Comments

• At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash.

Industry Context

In the biotechnology and pharmaceutical sectors, executive compensation often includes a significant equity component to align management incentives with long-term shareholder value. A CEO opting for stock in lieu of cash salary can be interpreted as a strong signal of confidence in the company's future prospects, a common practice among executives in growth-oriented industries.

Comparison to Industry Standards

• Many biotech and pharma executives receive a substantial portion of their compensation in equity, often through restricted stock units or options, to align their interests with long-term company performance.
• The practice of taking salary in stock, as seen with Dr. Armen, is a direct demonstration of commitment, similar to how executives at companies like Moderna or BioNTech have historically shown confidence through equity holdings during critical development phases.
• While the specific amount of 4,942 shares is relatively small in the context of total outstanding shares, the principle of foregoing cash for equity is a positive indicator of insider belief, a trend observed across various growth industries where leadership is heavily invested in the company's success.

Related Party Transactions

• Garo H. Armen, the Chairman and CEO, received 4,942 shares of common stock as salary, which is a transaction between the company and a related party (executive officer).

Stakeholder Impact

• Shareholders: The CEO's decision to take salary in stock may be viewed positively, signaling management's confidence in the company's long-term value and aligning executive interests with shareholder returns.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Agenus Inc., AGEN, Garo H. Armen, Insider Trading, Stock Compensation, CEO Salary, Equity Incentive Plan, Biotechnology, Pharmaceuticals